Our MDMA-analogue library has grown to over 150! An additional 19 compounds have been sent for safety screening.

These ‘next-generation’ MDMA-inspired compounds are aimed at treating conditions like Post-Traumatic Stress Disorder, Parkinson’s Disease and fibrotic disease – with some already in pre-clinical testing.

Read more: Emyria Grows MDMA Asset for Neuro & Mental Health Therapy | Emyria Investor Hub